UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Unicycive securities between March 29, 2024, and June 27, 2025 [2]. - The Complaint alleges that Unicycive's management made materially false and misleading statements regarding the company's business operations and compliance policies [3]. - Specific allegations include overstated readiness to meet FDA manufacturing compliance requirements and exaggerated regulatory prospects for the OLC NDA [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Unicycive have until October 14, 2025, to request appointment as lead plaintiff in the case [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC has a history of recovering significant amounts for investors in securities fraud cases [6].